Compare AXG & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXG | LBRX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Hong Kong | United States |
| Employees | 33 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.4M | 602.6M |
| IPO Year | N/A | N/A |
| Metric | AXG | LBRX |
|---|---|---|
| Price | $3.66 | $31.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | ★ 329.2K | 277.5K |
| Earning Date | 01-09-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.53 | N/A |
| Revenue Next Year | $54.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.69 | $13.40 |
| 52 Week High | $4.75 | $33.47 |
| Indicator | AXG | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 64.24 |
| Support Level | $3.25 | $21.90 |
| Resistance Level | $3.90 | $33.47 |
| Average True Range (ATR) | 0.20 | 1.91 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 27.91 | 76.08 |
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.